A citation-based method for searching scientific literature

Ruin Moaddel, Galia Abdrakhmanova, Joanna Kozak, Krzysztof Jozwiak, Lawrence Toll, Lucita Jimenez, Avraham Rosenberg, Thao Tran, Yingxian Xiao, Carlos A Zarate, Irving W Wainer. Eur J Pharmacol 2013
Times Cited: 115



Kanzo Suzuki, Elena Nosyreva, Kevin W Hunt, Ege T Kavalali, Lisa M Monteggia. Nature 2017
Times Cited: 110




List of shared articles



Times cited

Mechanisms of ketamine and its metabolites as antidepressants.
Evan M Hess, Lace M Riggs, Michael Michaelides, Todd D Gould. Biochem Pharmacol 2022
16

Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines.
Jaclyn N Highland, Patrick J Morris, Kylie M Konrath, Lace M Riggs, Natalie R Hagen, Panos Zanos, Chris F Powels, Ruin Moaddel, Craig J Thomas, Amy Q Wang,[...]. ACS Chem Neurosci 2022
5

Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders.
Vern Lewis, Brandon Rodrigue, Emily Arsenault, Molly Zhang, Fatimeh-Frouh Taghavi-Abkuh, Weverton Castro Coelho Silva, Mysa Myers, Edna Matta-Camacho, Argel Aguilar-Valles. J Neurochem 2022
0

Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search.
Jordi Bonaventura, Juan L Gomez, Meghan L Carlton, Sherry Lam, Marta Sanchez-Soto, Patrick J Morris, Ruin Moaddel, Hye Jin Kang, Panos Zanos, Todd D Gould,[...]. Mol Psychiatry 2022
6

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
Danilo De Gregorio, Argel Aguilar-Valles, Katrin H Preller, Boris Dov Heifets, Meghan Hibicke, Jennifer Mitchell, Gabriella Gobbi. J Neurosci 2021
39

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.
Jaclyn N Highland, Panos Zanos, Lace M Riggs, Polymnia Georgiou, Sarah M Clark, Patrick J Morris, Ruin Moaddel, Craig J Thomas, Carlos A Zarate, Edna F R Pereira,[...]. Pharmacol Rev 2021
33

Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity.
Eric S Schwenk, Basant Pradhan, Rohit Nalamasu, Lucas Stolle, Irving W Wainer, Michael Cirullo, Alexander Olson, Joseph V Pergolizzi, Marc C Torjman, Eugene R Viscusi. Curr Pain Headache Rep 2021
2

Ketamine: The final frontier or another depressing end?
Omar K Sial, Eric M Parise, Lyonna F Parise, Tamara Gnecco, Carlos A Bolaños-Guzmán. Behav Brain Res 2020
16

Ketamine's dose related multiple mechanisms of actions: Dissociative anesthetic to rapid antidepressant.
Eli Lavender, Mika Hirasawa-Fujita, Edward F Domino. Behav Brain Res 2020
16

Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma.
Greg I Elmer, Jenica D Tapocik, Cheryl L Mayo, Panos Zanos, Todd D Gould. Pharmacol Biochem Behav 2020
8

Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.
Todd D Gould, Carlos A Zarate, Scott M Thompson. Annu Rev Pharmacol Toxicol 2019
65

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.
Eric W Lumsden, Timothy A Troppoli, Scott J Myers, Panos Zanos, Yasco Aracava, Jan Kehr, Jacqueline Lovett, Sukhan Kim, Fu-Hua Wang, Staffan Schmidt,[...]. Proc Natl Acad Sci U S A 2019
79

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.
Panos Zanos, Jaclyn N Highland, Brent W Stewart, Polymnia Georgiou, Carleigh E Jenne, Jacqueline Lovett, Patrick J Morris, Craig J Thomas, Ruin Moaddel, Carlos A Zarate,[...]. Proc Natl Acad Sci U S A 2019
77

(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
Panos Zanos, Jaclyn N Highland, Xin Liu, Timothy A Troppoli, Polymnia Georgiou, Jacqueline Lovett, Patrick J Morris, Brent W Stewart, Craig J Thomas, Scott M Thompson,[...]. Br J Pharmacol 2019
45

The rapid-onset antidepressant effect of ketamine: More surprises?
R B Raffa, J V Pergolizzi, R Taylor. J Clin Pharm Ther 2018
2

Convergent Mechanisms Underlying Rapid Antidepressant Action.
Panos Zanos, Scott M Thompson, Ronald S Duman, Carlos A Zarate, Todd D Gould. CNS Drugs 2018
97

Stereochemical and structural effects of (2R,6R)-hydroxynorketamine on the mitochondrial metabolome in PC-12 cells.
Andréa T Faccio, Francisco J Ruperez, Nagendra S Singh, Santiago Angulo, Marina F M Tavares, Michel Bernier, Coral Barbas, Irving W Wainer. Biochim Biophys Acta Gen Subj 2018
11

Mechanisms of ketamine action as an antidepressant.
P Zanos, T D Gould. Mol Psychiatry 2018
384

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Lace M Riggs, Jaclyn N Highland, Polymnia Georgiou, Edna F R Pereira, Edson X Albuquerque, Craig J Thomas, Carlos A Zarate,[...]. Pharmacol Rev 2018
427

Zanos et al. reply.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Polymnia Georgiou, Jonathan Fischell, Greg I Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J Pribut, Nagendra S Singh,[...]. Nature 2017
21

Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites.
Patrick J Morris, Ruin Moaddel, Panos Zanos, Curtis E Moore, Todd D Gould, Carlos A Zarate, Craig J Thomas. Org Lett 2017
43

Hydroxynorketamine: Implications for the NMDA Receptor Hypothesis of Ketamine's Antidepressant Action.
Lily R Aleksandrova, Yu Tian Wang, Anthony G Phillips. Chronic Stress (Thousand Oaks) 2017
13